Aleix Prat

Sobre mi

Publicacions destacades

• TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy

  Autors:

  Martin, M; Stecklein, S R; Gluz, O; Villacampa, G; Monte-Millan, M;

  (...)

  Perou, C M; Villagrasa, P; Prat, A; Sharma, P; Harbeck, N.

  Veure llistat complet d'autors

  Referència: Annals Of Oncology 2025.

• A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies

  Autors:

  Conte, Benedetta; Braso-Maristany, Fara; Hernandez, Adela Rodriguez; Pascual, Tomas; Villacampa, Guillermo;

  (...)

  Villagrasa, Patricia; Staaf, Johan; Parker, Joel S; Perou, Charles M; Prat, Aleix.

  Veure llistat complet d'autors

  Referència: Ebiomedicine 2024.

• Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer

  Autors:

  Villacampa, G; Tung, N M; Pernas, S; Pare, L; Bueno-Muino, C;

  (...)

  Carey, L A; Mittendorf, E A; Martin, M; Prat, A; Tolaney, S M.

  Veure llistat complet d'autors

  Referència: Annals Of Oncology 2023.

• Patritumab Deruxtecan in Untreated Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Final Results from Part A of the Window-of-Opportunity SOLTI TOT-HER3 Pre-Operative Study

  Autors:

  Oliveira, M; Falato, C; Cejalvo, J M; Vila, M Margeli; Tolosa, P;

  (...)

  Sellami, D; Villacampa, G; Ferrero-Cafiero, J M; Pascual, T; Prat, A.

  Veure llistat complet d'autors

  Referència: Annals Of Oncology 2023.

• Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer

  Autors:

  Prat, Aleix; Braso-Maristany, Fara; Martinez-Saez, Olga; Sanfeliu, Esther; Xia, Youli;

  (...)

  Gonzalez-Farre, Blanca; Villagrasa, Patricia; Parker, Joel S; Perou, Charles M; Vivancos, Ana.

  Veure llistat complet d'autors

  Referència: Nature Communications 2023.

• HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial

  Autors:

  Guarneri, Valentina; Braso-Maristany, Fara; Vittoria Dieci, Maria; Griguolo, Gaia; Pare, Laia;

  (...)

  Villagrasa, Patricia; Parker, Joel S; Perou, Charles M; Conte, PierFranco; Prat, Aleix.

  Veure llistat complet d'autors

  Referència: Ebiomedicine 2022.

• Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies

  Autors:

  Prat, A; Chic, N; Martínez-Sáez, O; Brasó-Maristany, F; Paré, L;

  (...)

  Solovieff, N; Lteif, A; Babbar, N; Su, F; Taran, T.

  Veure llistat complet d'autors

  Referència: Journal Of Clinical Oncology 2021.

• A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

  Autors:

  Prat, Aleix; Guarneri, Valentina; Pare, Laia; Griguolo, Gaia; Pascual, Tomos;

  (...)

  Piacentini, Federico; D'Amico, Roberto; Tagtiapco, Enrico; Parker, Joel S; Conte, Pierfranco.

  Veure llistat complet d'autors

  Referència: Lancet Oncology 2020.

• Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial

  Autors:

  Prat, Aleix; Saura, Cristina; Pascual, Tomas; Hernando, Cristina; Munoz, Montserrat;

  (...)

  Lopez, Rafael; Celiz, Pamela; Ciruelos, Eva; Villagrasa, Patricia; Gavila, Joaquin.

  Veure llistat complet d'autors

  Referència: Lancet Oncology 2020.

• HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): An open-label, single-group, multicentre, phase 2 trial

  Autors:

  Llombart-Cussac, Antonio; Cortes, Javier; Pare, Laia; Galvan, Patricia; Bermejo, Begona;

  (...)

  Morales, Serafin; Oliveira, Mafalda; de la Pena, Lorena; Pelaez, Alexandra; Prat, Aleix.

  Veure llistat complet d'autors

  Referència: Lancet Oncology 2017.

Projectes destacats

• A European Cancer Image Platform Linked to Biological and Health Data for Next-Generation Artificial Intelligence and Precision Medicine in Oncology

  Investigador/a principal: Jordi Rimola Gibert, Aleix Prat Aparicio

  Finançador: European Commission

  Codi: CE_H2020_SC1_20_1s13

  Durada: 01/10/2020 - 30/09/2024

• RESCUER: Resistance Under Combinatorial Treatment in ER+ and ER- Breast Cancer.

  Investigador/a principal: Aleix Prat Aparicio

  Finançador: European Commission

  Codi: H2020-SC1-BHC-02-2019 / 847912-2

  Durada: 01/01/2020 - 31/12/2024

• Adoptive cell therapy using CD3+/PD1+ tumor infiltrating lymphocytes in patients with advanced breast cancer

  Investigador/a principal: Aleix Prat Aparicio

  Finançador: Asociación Española Contra el Cáncer

  Codi: GCAEC19010PRAT

  Durada: 01/12/2019 - 30/11/2024

• Identification of mechanisms of response to CDK4/6 inhibition in hormone receptor-positive breast cancer.

  Investigador/a principal: Aleix Prat Aparicio

  Finançador: Fundació La Marató de TV3

  Codi: 201935-30

  Durada: 30/07/2020 - 31/12/2023

• Desarrollo de un test basado en DNA tumoral circulante (ctDNA) para identificar los subtipos moleculares intrínsecos de cáncer de mama.

  Investigador/a principal: Aleix Prat Aparicio

  Finançador: I Premio M. Chiara Giorgetti

  Codi: CMM_CHIARAG19_001

  Durada: 01/02/2020 - 31/07/2021